Abstract: A protective member at least partially surrounds a desired length of pipe (such as a conventional landing string) and protects “umbilical” control line(s) or bundles, including pipe and umbilical line(s) installed within risers of subsea installations. At least one robust protective shell member is installed around at least a portion of a pipe string and forms at least one elongated channel. At least one umbilical control line is disposed within the elongated channel and is shielded against damage from inadvertent or unwanted abrasion, impact or other forces.

Abstract: Described herein are methods for treating a subject having or at risk of developing Gaucher disease, by administering one or more agents that increase expression and/or activity of glucocerebrosidase (GBA) and/or scavenger receptor class B member 2 (SCARB2), such as pluripotent cells that express GBA and/or SCARB2, and to the subject. Also disclosed are compositions comprising one or more agents that increase the expression and/or activity of GBA and/or SCARB2.

Abstract: Described herein are compositions and methods for treating a subject having or at risk of developing Pompe disease. For example, using the compositions and methods of the disclosure, a subject having or at risk of developing Pompe disease may be administered one or more cells that contain a transgene encoding acid-alpha glucosidase (GAA) fused to a glycosylation independent lysosomal targeting (GILT) tag (GILT. GAA), wherein the GILT tag is a human insulin-like growth factor II (IGF-II) mutein containing an Ala amino acid substitution at a position corresponding to Arg37 of SEQ ID NO: 15, such as a population of CD34+ hematopoietic stem or progenitor cells that express GILT. GAA, thereby treating or preventing Pompe disease.

Abstract: Described herein are compositions and methods for treating a subject having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease or Nasu-Hakola disease. For example, using the compositions and methods of the disclosure, a subject having or at risk of developing a neurocognitive disorder may be administered one or more cells that contain a transgene encoding triggering receptor expressed on myeloid cells two (TREM2), such as a population of CD34+ hematopoietic stem or progenitor cells that express TREM2, thereby treating or preventing the disorder.

Abstract: A protective member at least partially surrounds a desired length of pipe (such as a conventional landing string) and protects “umbilical” control line(s) or bundles, including pipe and umbilical line(s) installed within risers of subsea installations. At least one robust protective shell member is installed around at least a portion of a pipe string and forms at least one elongated channel. At least one umbilical control line is disposed within the elongated channel and is shielded against damage from inadvertent or unwanted abrasion, impact or other forces.

Abstract: Systems and techniques are described for efficient, general-purpose, and potentially decentralized databases, distributed storage systems, version control systems, and/or other types of data repositories. Data is represented in a database system in such a way that any value is represented by a unique identifier which is derived from the value itself. Any database peer in the system will derive an identical identifier from the same logical value. The identifier for a value may be derived using a variety of mechanisms, including, without limitation, a hash function known to all peers in the system. The values may be organized hierarchically as a tree of nodes. Any two peers storing the same logical value will deterministically represent that value with a graph, such as the described “Prolly” tree, having the same topology and hash value, irrespective of possibly differing sequences of mutations which caused each to arrive at the same final value.

Abstract: Described herein are compositions and methods for treating a patient having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease, Parkinson's disease, and/or a frontotemporal lobar dementia. Using the compositions and methods of the disclosure, a patient, such as an adult human patient, may be provided one or more agents that elevate the expression and/or activity levels of a protein or series of proteins whose deficiency is associated with the corresponding disease. Exemplary agents that may be used in conjunction with the compositions and methods of the disclosure for this purpose include cells, such as cells, that contain nucleic acids encoding the protein or proteins of interest, as well as vectors, such as viral vectors, encoding the protein or proteins of interest. Additional examples of such agents include the protein or proteins themselves, as well as interfering RNA molecules that stimulate their endogenous expression.

Abstract: Described herein are compositions and methods for treating a subject having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease or Nasu-Hakola disease. For example, using the compositions and methods of the disclosure, a subject having or at risk of developing a neurocognitive disorder may be administered one or more cells that contain a transgene encoding triggering receptor expressed on myeloid cells two (TREM2), such as a population of CD34+ hematopoietic stem or progenitor cells that express TREM2, thereby treating or preventing the disorder.

Abstract: Described herein are methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis, by administering cells that contain a transgene encoding a progranulin (PGRN) or a granulin (GRN) or cells that express the PGRN or the GRN to the subject. Also disclosed are compositions comprising cells containing the transgene encoding the PGRN or the GRN.

Abstract: Systems and techniques are described for efficient, general-purpose, and potentially decentralized databases, distributed storage systems, version control systems, and/or other types of data repositories. Data is represented in a database system in such a way that any value is represented by a unique identifier which is derived from the value itself. Any database peer in the system will derive an identical identifier from the same logical value. The identifier for a value may be derived using a variety of mechanisms, including, without limitation, a hash function known to all peers in the system. The values may be organized hierarchically as a tree of nodes. Any two peers storing the same logical value will deterministically represent that value with a graph, such as the described “Prolly” tree, having the same topology and hash value, irrespective of possibly differing sequences of mutations which caused each to arrive at the same final value.

Abstract: Systems and techniques are described for efficient, general-purpose, and potentially decentralized databases, distributed storage systems, version control systems, and/or other types of data repositories. Data is represented in a database system in such a way that any value is represented by a unique identifier which is derived from the value itself. Any database peer in the system will derive an identical identifier from the same logical value. The identifier for a value may be derived using a variety of mechanisms, including, without limitation, a hash function known to all peers in the system. The values may be organized hierarchically as a tree of nodes. Any two peers storing the same logical value will deterministically represent that value with a graph, such as the described “Prolly” tree, having the same topology and hash value, irrespective of possibly differing sequences of mutations which caused each to arrive at the same final value.

Abstract: Described herein are methods for treating a subject having or at risk of developing Parkinson's disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents.

Abstract: Uncured epoxy resin for use in making prepreg for aerospace applications. The resin includes an epoxy resin component comprising difunctional epoxy resin, trifunctional epoxy resin and/or tetrafunctional epoxy resin and a sufficient amount of [3-(4-aminobenzoyl) oxyphenyl]4-aminobenzoate (3-ABOAB), as a curing agent, such that the uncured resin can be stored at room temperature of at least 6 weeks and wherein the uncured resin can be fully cured in no more than 2 hours at a temperature of between 175° C. and 185° C.

Abstract: Amino benzoates have been found to be useful curing agents for epoxy resins particularly para amino benzoates containing at least two primary amine groups and at least two carboxyl moieties, the amino benzoates are particularly useful as curatives in prepregs.

Abstract: Amino benzoates have been found to be useful curing agents for epoxy resins particularly para amino benzoates containing at least two primary amine groups and at least two carboxyl moieties, the amino benzoates are particularly useful as curatives in prepregs.

Abstract: Uncured epoxy resin for use in making prepreg for aerospace applications. The resin includes an epoxy resin component comprising difunctional epoxy resin, trifunctional epoxy resin and/or tetrafunctional epoxy resin and a sufficient amount of [3-(4-aminobenzoyl) oxyphenyl] 4-aminobenzoate (3-ABOAB), as a curing agent, such that the uncured resin can be stored at room temperature of at least 6 weeks and wherein the uncured resin can be fully cured in no more than 2 hours at a temperature of between 175° C. and 185° C.

Abstract: Liquid alkoxy-substituted methylene bis anilines have been found to be useful curing agents for epoxy resins and have also been found to be more readily formulated with epoxy resins, the substituents on the aromatic groups of the methylene bis anilines include an alkoxy group and/or the mixtures of materials are selected in order to obtain the liquid products.

Abstract: A method for acquiring analytical information may be provided. The method may include providing a database configured to store user specific data and providing a user interface for displaying, inputting, or analyzing the data. A customer interface may be provided to allow for customer interaction with a business, retailer, or service provider. Customer data may be measured through online interactions, signals from mobile devices, and in-store interactions. User specific data and general customer data may be compiled in the database and feedback may be generated based on the data and presented through the user interface.

Abstract: A method for acquiring analytical information may be provided. The method may include providing a database configured to store user specific data and providing a user interface for displaying, inputting, or analyzing the data. A customer interface may be provided to allow for customer interaction with a business, retailer, or service provider. Customer data may be measured through online interactions, signals from mobile devices, and in-store interactions. User specific data and general customer data may be compiled in the database and feedback may be generated based on the data and presented through the user interface.